Patents by Inventor Thomas J. Kelly
Thomas J. Kelly has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11931492Abstract: A system and method for balancing flows of renal replacement fluid is disclosed. The method uses pressure controls and pressure sensing devices to more precisely meter and balance the flow of fresh dialysate and spent dialysate. The balancing system may use one or two balancing devices, such as a balance tube, a tortuous path, or a balance chamber.Type: GrantFiled: June 30, 2021Date of Patent: March 19, 2024Assignees: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE SAInventors: Michael E. Hogard, Donald D. Busby, Robert W. Childers, Yuanpang Samuel Ding, Katherine M. Holian, Mark E. Jablonski, Thomas D. Kelly, Shincy J. Maliekkal, Rodolfo G. Roger, Donald A. Smith, Atif M. Yardimci, Ying-Cheng Lo
-
Publication number: 20240073566Abstract: Advanced hologram techniques pre-calculate holograms to be displayed on an LCoS switch panel of a wavelength selective switch (WSS) module. The holograms are generated offline and are then stored on the WSS module for later retrieval. Each of the holograms is associated with a defined parameter, such as an attenuation level, and each of the holograms is configured to create a reconfigurable phase grating profile or pattern of the pixels of the LCoS switch panel. Each phase pattern selectively directs desired diffraction orders of optical channels from the LCoS switch panel for output to selected ports and selectively directs undesired diffraction orders away from the ports and at a desired attenuation level. During operation, the WSS module can retrieve the stored holograms. Interpolation can determine intermediate holograms between parameter values, and a ramp function can be added to the pattern to account for steering adjustments.Type: ApplicationFiled: August 25, 2022Publication date: February 29, 2024Inventors: Alan A. FENNEMA, Haijun Yuan, Wilfredo C. NANITA, Oswald CORREYA, Jack R KELLY, Thomas J. Schwartz
-
Patent number: 11915611Abstract: A medical training device facilitating practice of a task-specific medical procedure for the treatment of a traumatic injury is presented. The invention includes a simulant with or without a simulated wound and an optional case adapted to receive the simulant. For embodiments specific to establishing an emergency airway, the simulant includes a compressible body with an outer covering and an insert with an inner covering. The compressible body and the outer covering approximate a neck. The insert approximates a trachea. The insert is disposed within and separable from the compressible body. The inner covering is disposed between the outer covering and the insert. For embodiments specific to an intramuscular injection, the simulant includes a compressible body, a slot, and a fill. The compressible body approximates a muscle. The slot extends into the compressible body. The slot is adapted to receive the fill. The fill is removably secured within the slot.Type: GrantFiled: February 20, 2023Date of Patent: February 27, 2024Assignee: Techline Technologies, Inc.Inventors: Daniel J. Parry, David J. Parry, Jr., Anthony R. Grillo, Thomas D. Kelly
-
Publication number: 20230255929Abstract: The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B): or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin.Type: ApplicationFiled: April 24, 2023Publication date: August 17, 2023Inventors: Mark G. Frattini, Hakim Djaballah, Thomas J. Kelly
-
Patent number: 11666550Abstract: The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B): or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin.Type: GrantFiled: May 26, 2021Date of Patent: June 6, 2023Assignee: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCHInventors: Mark G. Frattini, Hakim Djaballah, Thomas J. Kelly
-
Publication number: 20210283099Abstract: The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B): or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin.Type: ApplicationFiled: May 26, 2021Publication date: September 16, 2021Inventors: Mark G. Frattini, Hakim Djaballah, Thomas J. Kelly
-
Patent number: 11045446Abstract: The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B): or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin.Type: GrantFiled: November 13, 2018Date of Patent: June 29, 2021Assignee: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCHInventors: Mark G. Frattini, Hakim Djaballah, Thomas J. Kelly
-
Publication number: 20190314329Abstract: The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B): or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin.Type: ApplicationFiled: November 13, 2018Publication date: October 17, 2019Inventors: Mark G. Frattini, Hakim Djaballah, Thomas J. Kelly
-
Patent number: 10372463Abstract: A technique provisions a computerized device with a main operating system. The technique involves loading, while the computerized device operates as a preboot execution environment (PXE) protocol client, a limited boot image from a PXE server over a network (e.g., booting the limited boot image using the trivial file transfer protocol or TFTP). The technique further involves executing the limited boot image loaded from the PXE server to operate the computerized device as an advanced protocol provisioned client. The technique further involves downloading, while the computerized device executes the limited boot image to operate as the advanced protocol provisioned client, the main operating system into local memory from an operating system server over the network (e.g., booting the main operating system using the file transfer protocol or FTP). The computerized device may store a copy of the main operating system in a local non-volatile cache if available.Type: GrantFiled: November 27, 2013Date of Patent: August 6, 2019Assignee: EMC IP Holding Company LLCInventors: Kevin P. Twomey, Daniel J. Roche, Xiao Lou, Thomas J. Kelly, Isaias A. Barinas, Frank T. Smith
-
Patent number: 10123992Abstract: The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B): or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin.Type: GrantFiled: October 10, 2017Date of Patent: November 13, 2018Assignee: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCHInventors: Mark G. Frattini, Hakim Djaballah, Thomas J. Kelly
-
Patent number: 10062042Abstract: A technique assigns tasks to workers within a work area. The technique utilizes electronic circuitry which can be disposed at a single location (e.g., a server), or distributed among multiple locations (e.g., in the cloud). The technique involves receiving task entries which (i) identify tasks in need of attention and (ii) define task requirements for performing the tasks. The technique further involves generating task assignments based on matching the task entries to worker profiles which (i) identify workers who are available for task assignment and (ii) define worker characteristics of the workers. The technique further involves providing the task assignments to the workers while the workers are distributed among different locations within the work area. The task assignments direct the workers to perform the tasks identified by the task entries in accordance with the task requirements defined by the task entries.Type: GrantFiled: September 25, 2012Date of Patent: August 28, 2018Assignee: EMC IP Holding Company LLCInventors: Thomas J. Kelly, John R. Carmody, Kevin P. Twomey, Frank T. Smith
-
Publication number: 20180125815Abstract: The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B): or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin.Type: ApplicationFiled: October 10, 2017Publication date: May 10, 2018Applicant: Sloan-Kettering Institute for Cancer ResearchInventors: Mark G. Frattini, Hakim Djaballah, Thomas J. Kelly
-
Patent number: 9782386Abstract: The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B): or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin.Type: GrantFiled: November 11, 2016Date of Patent: October 10, 2017Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Mark G. Frattini, Hakim Djaballah, Thomas J. Kelly
-
Patent number: 9692656Abstract: A policy distribution server provides, on a subscription basis, policy updates to effect desired behaviors of network intermediary devices. The policy updates may specify caching policies, and may in some instances, include instructions for data collection by the network intermediary devices. Data collected in accordance with such instructions may be used to inform future policy updates distributed to the network intermediary devices.Type: GrantFiled: January 8, 2016Date of Patent: June 27, 2017Assignee: Symantec CorporationInventors: Kevin Porter, Thomas J. Kelly, Marcin Lukasz Lizon, Darrell Long, Eric Maki, Kim Tremblay, Jennifer Vance
-
Publication number: 20170119731Abstract: The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B): or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin.Type: ApplicationFiled: November 11, 2016Publication date: May 4, 2017Applicant: Sloan-Kettering Institute for Cancer ResearchInventors: Mark G. Frattini, Hakim Djaballah, Thomas J. Kelly
-
Patent number: 9492427Abstract: The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B): or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin.Type: GrantFiled: November 9, 2015Date of Patent: November 15, 2016Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Mark G. Frattini, Hakim Djaballah, Thomas J. Kelly
-
Publication number: 20160127189Abstract: A policy distribution server provides, on a subscription basis, policy updates to effect desired behaviors of network intermediary devices. The policy updates may specify caching policies, and may in some instances, include instructions for data collection by the network intermediary devices. Data collected in accordance with such instructions may be used to inform future policy updates distributed to the network intermediary devices.Type: ApplicationFiled: January 8, 2016Publication date: May 5, 2016Inventors: Kevin Porter, Thomas J. Kelly, Marcin Lukasz Lizon, Darrell Long, Eric Maki, Kim Tremblay, Jennifer Vance
-
Publication number: 20160058733Abstract: The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B): or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin.Type: ApplicationFiled: November 9, 2015Publication date: March 3, 2016Applicant: Sloan-Kettering Institute for Cancer ResearchInventors: Mark G. Frattini, Hakim Djaballah, Thomas J. Kelly
-
Patent number: 9237068Abstract: A policy distribution server provides, on a subscription basis, policy updates to effect desired behaviors of network intermediary devices. The policy updates may specify caching policies, and may in some instances, include instructions for data collection by the network intermediary devices. Data collected in accordance with such instructions may be used to inform future policy updates distributed to the network intermediary devices.Type: GrantFiled: January 30, 2011Date of Patent: January 12, 2016Assignee: Blue Coat Systems, Inc.Inventors: Kevin Porter, Thomas J. Kelly, Marcin Lukasz Lizon, Darrell Long, Eric Maki, Kim Tremblay, Jennifer Vance
-
Patent number: 9180105Abstract: The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B) or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin.Type: GrantFiled: March 8, 2011Date of Patent: November 10, 2015Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Mark G. Frattini, Hakim Djaballah, Thomas J. Kelly